Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 treatment. The 3-year relapse-free survival rate was 74%, and the overall ...
Atezolizumab combined with R-GemOx shows favorable safety and efficacy in relapsed/refractory DLBCL, especially in transformed FL cases. The study reported a 59% overall response rate and a 33% ...
The field of cancer biology has recently recognized the significance of immunogenic cell death (ICD), a process by which dying cells emit alarm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results